RayKnowChina Research Map
Shortlist0

Peking University Health Science Center

北京大学医学部

BeijingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.4%Leads under 1 in 100 of China's research papers on NPC

Led 10 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 112025
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseEBV & screening

Hospitals counted here

  1. Peking University Shenzhen Hospital8
  2. Peking University Cancer Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Long-term recurrence and brain metastasis of nasopharyngeal carcinoma mimicking cystic radiation encephalopathy relapse: a case report.2021BMC neurologyFree full text
  2. DVH Prediction for VMAT in NPC with GRU-RNN: An Improved Method by Considering Biological Effects.2021BioMed research internationalFree full text
  3. A three-miRNA panel in serum: Serving as a novel diagnostic method for nasopharyngeal carcinoma.2025The International journal of biological markers
  4. Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy.2024Cancer medicineFree full text
  5. Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma.2023Journal of translational medicineFree full text
Trials on ClinicalTrials.gov6
  1. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  2. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  3. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  4. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  5. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  6. To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal CancerStatus unknownNCT05198531Study sitePhase 1/Phase 2Start 2022-01

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
3.1%Leads about 1 in 32 of China's research papers on ESCC ▲ from 2.2%

Led 90 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
6
Research papers it led
90
Trials it led
33
Share of China's trials
5.8%
Share of the world's papers
2.1%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025
ThemesSurgeryNeoadjuvant & combined treatmentMolecular markers & genomics

Hospitals counted here

  1. Peking University Cancer Hospital82
  2. Peking University People's Hospital2
  3. Peking University Shenzhen Hospital Counted in the group total2
  4. Peking University International Hospital Counted in the group total1
  5. Peking University Third Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  2. Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.2024Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  3. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.2022Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  4. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.2022BMJ (Clinical research ed.)RCTFree full text
  5. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Cli2021JAMA surgeryRCTFree full text
Trials on ClinicalTrials.gov6
  1. Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and SurgeryNot yet recruitingNCT07822906Lead sponsorStart 2026-10
  2. A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous CarcinomaRecruitingNCT06869213Lead sponsorPhase 2Start 2025-03
  3. QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07049185Lead sponsorPhase 2Start 2025-09
  4. Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT07312578Lead sponsorPhase 2Start 2025-11
  5. Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Lead sponsorPhase 2Start 2024-11
  6. Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT05386056Lead sponsorPhase 2Start 2022-12

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.0%Leads about 1 in 100 of China's research papers on HCC

Led 148 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
9
Research papers it led
148
Trials it led
22
Share of China's trials
1.5%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Hospitals counted here

  1. Peking University Cancer Hospital42
  2. Peking University People's Hospital24
  3. Peking University Shenzhen Hospital22
  4. Peking University First Hospital19
  5. Peking University Third Hospital11
  6. Peking University International Hospital Counted in the group total6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  2. A Multicenter Randomized Controlled Study of Contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions.2022RadiologyRCT
  3. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.2022RadiologyRCT
  4. NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.2025GutFree full text
  5. Methodological challenges in studying immune-suppressive neutrophils in HCC models.2024Journal of hepatology
Trials on ClinicalTrials.gov6
  1. 68Ga-SorB PET/CT Imaging in Patients With Solid TumorsRecruitingNCT07760012Lead sponsorN/AStart 2026-08
  2. GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular CarcinomaRecruitingNCT07795437Lead sponsorN/AStart 2026-08
  3. 18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsRecruitingNCT07557225Lead sponsorN/AStart 2026-04
  4. SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT07882056Lead sponsorPhase 2Start 2026-10
  5. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Lead sponsorN/AStart 2025-06
  6. Phase I Study of OriC902 in Treatment of Advanced HCCRecruitingNCT06891742Lead sponsorPhase 1Start 2025-02

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
3.3%Leads about 1 in 30 of China's research papers on Stomach cancer

Led 323 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
15
Research papers it led
323
Trials it led
79
Share of China's trials
5.4%
Share of the world's papers
1.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseChemotherapy & combined treatment

Hospitals counted here

  1. Peking University Cancer Hospital223
  2. Peking University First Hospital27
  3. Peking University Third Hospital24
  4. Peking University People's Hospital21
  5. Peking University Shenzhen Hospital8
  6. Third Hospital of Peking University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, p2025Lancet (London, England)RCT
  2. Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.2025JAMA oncologyRCTFree full text
  3. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.2025JAMARCTFree full text
  4. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.2025Nature medicineRCT
  5. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.2024Nature medicineRCT
Trials on ClinicalTrials.gov6
  1. Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI CancersNot yet recruitingNCT07656740Lead sponsorStart 2026-06
  2. The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer ImmunotherapyRecruitingNCT07039474Lead sponsorStart 2026-09
  3. LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)RecruitingNCT07857668Lead sponsorStart 2026-08
  4. ctDNA-MRD Monitoring After Resection in Gastric CancerRecruitingNCT06893133Lead sponsorStart 2025-04
  5. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Lead sponsorPhase 2Start 2025-12
  6. Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric CancerNot yet recruitingNCT07018063Lead sponsorPhase 2Start 2025-10

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
11.4%Leads about 1 in 9 of China's research papers on Chordoma ▼ from 14.8%

Led 12 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
2.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Hospitals counted here

  1. Peking University People's Hospital6
  2. Peking University Third Hospital6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
3.3%Leads about 1 in 30 of China's research papers on Osteosarcoma

Led 74 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
3
Research papers it led
74
Trials it led
21
Share of China's trials
36.2%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025
Papers it led5
  1. Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.2025Nature communicationsRCT
  2. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  3. Evaluating the Impact of Habitat Analysis via IVIM and DCE-MRI on Neoadjuvant Chemotherapy Outcomes in Osteosarcoma Patients: A Preliminary Study.2026Journal of imaging informatics in medicine
  4. Soft tissue reconstruction of tumor-related proximal tibial hemiarthroplasty using synthetic mesh combined with a medial gastrocnemius flap.2025Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology
  5. The clinical outcomes of joint-preserving endoprosthesis reconstruction for primary sarcomas about the knee.2025Journal of orthopaedic surgery and research
Trials on ClinicalTrials.gov6
  1. Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaRecruitingNCT07479732Lead sponsorPhase 1/Phase 2Start 2026-03
  2. 68Ga-B7-H3 Nanobody ImmunoPET in OsteosarcomaRecruitingNCT07774533Lead sponsorEarly phase 1Start 2026-04
  3. Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingNCT06714383Lead sponsorPhase 2Start 2024-11
  4. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06
  5. the Exploration of MTAP Deletion in Osteosarcoma by ImmunohistochemistryActive, not recruitingNCT07593573Lead sponsorStart 2025-12
  6. B7-H3 NIR Imaging for Osteosarcoma SurgeryRecruitingNCT06778603Lead sponsorPhase 1/Phase 2Start 2024-01

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
5.3%Leads about 1 in 19 of China's research papers on Gastrointestinal stromal tumour

Led 28 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
3
Research papers it led
28
Trials it led
11
Share of China's trials
14.9%
Share of the world's papers
1.7%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
Papers it led5
  1. Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial.2025CancerRCT
  2. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.2024European journal of cancer (Oxford, England : 1990)RCT
  3. Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.2023European radiologyRCT
  4. Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.2021BMC gastroenterologyRCT
  5. Mutational landscape of gastrointestinal stromal tumors using next-generation sequencing of a 73-gene panel.2025World journal of surgical oncology
Trials on ClinicalTrials.gov6
  1. Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingNCT07559864Lead sponsorPhase 2Start 2025-07
  2. MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMTRecruitingNCT06748690Lead sponsorN/AStart 2024-01
  3. Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRDRecruitingNCT05408897Lead sponsorStart 2022-01
  4. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  5. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Study sitePhase 2Start 2021-08
  6. Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal JunctionEnrolling by invitationNCT07550582Lead sponsorPhase 2Start 2026-04

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.0%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 11 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Peking University First Hospital6
  2. Peking University Shenzhen Hospital1
  3. Peking University Cancer Hospital1
  4. Aerospace Center Hospital1
  5. Civil Aviation General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
8.6%Leads about 1 in 12 of China's research papers on Ewing sarcoma ▲ from 6.0%

Led 14 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
2
Research papers it led
14
Trials it led
6
Share of China's trials
37.5%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 002025
Papers it led5
  1. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  2. Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.2024Diagnostic pathology
  3. Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.2023BMC medical imaging
  4. Primary ewing sarcoma in the uterine cervix with multiple bone metastases.2022Archives of gynecology and obstetrics
  5. Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.2022BMC cancer
Trials on ClinicalTrials.gov6
  1. Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing SarcomaRecruitingNCT07725783Lead sponsorStart 2025-09
  2. Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing SarcomaRecruitingNCT06340204Lead sponsorPhase 1Start 2024-03
  3. A Study of DXC008 in Patients With Prostate Cancer and Other Solid TumorsRecruitingNCT06926283Study sitePhase 1Start 2025-05
  4. Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing SarcomaNot yet recruitingNCT07620431Lead sponsorStart 2026-06
  5. Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis AssessmentActive, not recruitingNCT06850506Lead sponsorStart 2024-09
  6. Irinotecan and Temozolomide for Ewing SarcomaStatus unknownNCT03359005Lead sponsorPhase 2Start 2018-02

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
3.0%Leads about 1 in 34 of China's research papers on Myeloma

Led 50 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
10
Research papers it led
50
Trials it led
16
Share of China's trials
3.3%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025
ThemesDiagnosis, MRD & riskDrug combinationsBispecific & antibody drugs
Papers it led5
  1. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.2023Annals of hematologyRCTFree full text
  2. Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.2023Clinical lymphoma, myeloma & leukemiaRCT
  3. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.2021Clinical lymphoma, myeloma & leukemiaRCT
  4. Minimal Clonal Plasma Cell Contamination of Peripheral Stem Cell Grafts Has an Adverse Prognostic Impact in Patients with Multiple Myeloma Undergoing Autologous Transplantation.2026Acta haematologica
  5. Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem ce2026Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Trials on ClinicalTrials.gov6
  1. GPRC5D Targeted PET/CT Imaging in Plasma Cell DisordersRecruitingNCT07660939Lead sponsorPhase 1Start 2026-06
  2. ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By ElranatamabNot yet recruitingNCT07320326Lead sponsorStart 2025-12
  3. A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple MyelomaRecruitingNCT06717113Lead sponsorEarly phase 1Start 2025-04
  4. Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07296627Lead sponsorStart 2025-07
  5. 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Lead sponsorPhase 2/Phase 3Start 2025-12
  6. KPD Consolidation After ASCT in NDMM PatientsRecruitingNCT06879379Lead sponsorPhase 2/Phase 3Start 2025-03

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
8.4%Leads about 1 in 12 of China's research papers on B-ALL

Led 19 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
4
Research papers it led
19
Trials it led
4
Share of China's trials
1.6%
Share of the world's papers
1.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesChildrenPhiladelphia chromosome & geneticsCAR-T & cell therapy

Hospitals counted here

  1. Peking University People's Hospital19

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance.2025Frontiers in immunologyFree full text
  2. Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.2025Leukemia & lymphoma
  3. Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.2024Journal of translational medicineFree full text
  4. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.2024Clinical lymphoma, myeloma & leukemia
  5. CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.2024Cancer research and treatmentFree full text
Trials on ClinicalTrials.gov6
  1. Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCTNot yet recruitingNCT07919470Lead sponsorN/AStart 2026-11
  2. CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTRecruitingNCT07441291Lead sponsorPhase 3Start 2025-11
  3. Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALLRecruitingNCT06880913Lead sponsorPhase 1/Phase 2Start 2024-11
  4. Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06581081Lead sponsorN/AStart 2024-10
  5. Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Study sitePhase 1/Phase 2Start 2026-03
  6. Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALLRecruitingNCT07244406Study sitePhase 2Start 2025-01

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
7.3%Leads about 1 in 14 of China's research papers on Aplastic anaemia

Led 30 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
3
Research papers it led
30
Trials it led
5
Share of China's trials
5.1%
Share of the world's papers
1.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesStem cell transplantChildrenInfection & supportive care

Hospitals counted here

  1. Peking University People's Hospital29
  2. Peking University First Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling.2024Signal transduction and targeted therapyFree full text
  2. The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51-60 Years: A Retrospective Stu2025Clinical transplantation
  3. The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.2025Annals of hematologyFree full text
  4. Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.2025Cytotherapy
  5. G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.2025Transplantation and cellular therapy
Trials on ClinicalTrials.gov5
  1. A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAARecruitingNCT07586735Lead sponsorStart 2026-06
  2. Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic AnemiaRecruitingNCT07629947Lead sponsorN/AStart 2026-06
  3. A Prediction Model in Pregnant Women With Aplastic AnemiaRecruitingNCT07101770Lead sponsorStart 2025-11
  4. The Optimization of Conditioning Regimen for HLA Matched HSCT in SAAStatus unknownNCT06069180Lead sponsorPhase 4Start 2023-11
  5. Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAAStatus unknownNCT03821987Lead sponsorN/AStart 2018-12

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
2.3%Leads about 1 in 44 of China's research papers on HLH

Led 9 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
1
Research papers it led
9
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesEBV & infection triggersDiagnosis & prognosisLymphoma & cancer-related HLH

Hospitals counted here

  1. Peking University People's Hospital7
  2. Peking University First Hospital1
  3. Ditan Teaching Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.2025Lupus science & medicineFree full text
  2. Secondary Hemophagocytic Lymphohistiocytosis Syndrome Developing in a Patient With Chronic Lymphocytic Leukemia Under a Long-term Ibrutinib Therapy: A Case Report and Literature Review.2025Journal of immunotherapy (Hagerstown, Md. : 1997)Free full text
  3. COX Regression Analysis and Mortality Risk Prediction Model of 85 Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.2024British journal of hospital medicine (London, England : 2005)
  4. Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort.2024Annals of hematology
  5. A predictive model for identifying secondary underlying diseases of hemophagocytic lymphohistiocytosis.2023Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov3
  1. Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell TransplantationRecruitingNCT07905066Lead sponsorStart 2026-10
  2. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
  3. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.1%Leads about 1 in 91 of China's research papers on Haemophilia A New since 2021

Led 3 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
1
Research papers it led
3
Trials it led
1
Share of China's trials
1.2%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Peking University First Hospital1
  2. Peking University Third Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征
11.1%Leads about 1 in 9 of China's research papers on Atypical haemolytic uraemic syndrome ▼ from 23.1%

Led 3 of 27 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (11.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Peking University First Hospital2
  2. Peking University Shenzhen Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
6.2%Leads about 1 in 16 of China's research papers on Thrombotic thrombocytopenic purpura ▼ from 8.7%

Led 4 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
2
Research papers it led
4
Trials it led
2
Share of China's trials
33.3%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. Peking University People's Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
2.9%Leads about 1 in 34 of China's research papers on Fanconi anaemia New since 2021

Led 2 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Peking University People's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.6%Leads under 1 in 100 of China's research papers on NMOSD ▼ from 1.8%

Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
1
Research papers it led
3
Trials it led
1
Share of China's trials
1.3%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025
ThemesAntibodies & diagnosisPregnancy, children, older adultsBiologic drugs

Hospitals counted here

  1. Peking University Third Hospital2
  2. Peking University First Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
8.9%Leads about 1 in 11 of China's research papers on IgG4-RD ▼ from 12.8%

Led 22 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
1
Research papers it led
22
Trials it led
2
Share of China's trials
4.7%
Share of the world's papers
1.8%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 442025
ThemesDiagnosis & look-alikesHead, eye socket & salivary glandsKidney, retroperitoneum & vessels

Hospitals counted here

  1. Peking University People's Hospital12
  2. Peking University First Hospital5
  3. Peking University Third Hospital2
  4. Peking University Shenzhen Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.4%Leads about 1 in 71 of China's research papers on Myasthenia gravis ▲ from 0.4%

Led 7 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 222025
ThemesCrisis & intensive careStandard immunotherapyBiologic & complement drugs

Hospitals counted here

  1. Peking University People's Hospital3
  2. Peking University First Hospital3
  3. Peking University Third Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
2.5%Leads about 1 in 40 of China's research papers on Moyamoya ▲ from 0.4%

Led 9 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
1
Share of China's trials
3.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesGeneticsImaging & blood flowRevascularisation surgery

Hospitals counted here

  1. Peking University International Hospital6
  2. Peking University Third Hospital2
  3. Peking University Shenzhen Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
0.9%Leads under 1 in 100 of China's research papers on Biliary atresia New since 2021

Led 2 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025
ThemesScreening & diagnosisKasai operationLiver transplant

Hospitals counted here

  1. Pediatrics-Peking University Teaching Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
0.4%Leads under 1 in 100 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 3.2%

Led 1 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Peking University First Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis.2021Neurology(R) neuroimmunology & neuroinflammation

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
2.7%Leads about 1 in 37 of China's research papers on Takayasu arteritis

Led 5 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
2
Share of China's trials
8.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 112025

Hospitals counted here

  1. Pediatrics-Peking University Teaching Hospital2
  2. Peking University People's Hospital1
  3. Peking University Third Hospital1
  4. Peking University First Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.0%Leads about 1 in 99 of China's research papers on Idiopathic pulmonary fibrosis ▲ from 0.3%

Led 10 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

Hospitals counted here

  1. Peking University First Hospital4
  2. Peking University People's Hospital3
  3. Peking University Third Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Patient journey and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis (IPFLife) in China: a sequential exploratory mixed methods research protocol.2025BMJ open
  2. Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: a case control study.2024Clinical rheumatology
  3. Respiratory infection risk in primary Sjögren's syndrome complicated with interstitial lung disease: a retrospective study.2024Clinical rheumatology
  4. Pulmonary tuberculosis associated acute fibrinous and organizing pneumonia: A case report and literature review.2023The clinical respiratory journal
  5. Patterns of Interstitial Lung Disease and Prognosis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.2023Respiration; international review of thoracic diseases
Trials on ClinicalTrials.gov5
  1. Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary FibrosisStatus unknownNCT06629623Lead sponsorStart 2024-07
  2. Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06230822Study sitePhase 1Start 2024-03
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  5. Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Study sitePhase 3Start 2012-06

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
7.7%Leads about 1 in 13 of China's research papers on Amyotrophic lateral sclerosis

Led 60 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
2
Research papers it led
60
Trials it led
23
Share of China's trials
41.8%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

Hospitals counted here

  1. Peking University Third Hospital52
  2. Peking University First Hospital2
  3. Peking University Shenzhen Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.2025JAMA network openRCT
  2. Neutrophils Are Associated with Higher Risk of Incident Amyotrophic Lateral Sclerosis in a BMI- and Age-Dependent Manner.2023Annals of neurology
  3. Amyotrophic Lateral Sclerosis With Concurrent LHON-associated m.14484T>C Mutation: A Case Report and Literature Review.2025Revista de neurologia
  4. Characteristics and influencing factors of pain in amyotrophic lateral sclerosis: a focus on symptom management.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. Unveiling structural damage of the corpus callosum in amyotrophic lateral sclerosis through diffusion tensor imaging and spread direction perspectives.2025Annals of medicine
Trials on ClinicalTrials.gov6
  1. Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS PatientsRecruitingNCT05923905Lead sponsorPhase 4Start 2023-01
  2. Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT04454892Lead sponsorStart 2019-11
  3. A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT07082192Study sitePhase 2/Phase 3Start 2025-10
  4. The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral SclerosisRecruitingNCT07118319Study sitePhase 1Start 2025-09
  5. A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)Active, not recruitingNCT07223723Lead sponsorPhase 4Start 2025-12
  6. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral SclerosisNot yet recruitingNCT06645197Lead sponsorEarly phase 1Start 2024-10

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
1.8%Leads about 1 in 55 of China's research papers on Spinal muscular atrophy New since 2021

Led 1 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
1
Research papers it led
1
Trials it led
2
Share of China's trials
6.7%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Peking University First Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
12.3%Leads about 1 in 8 of China's research papers on Fabry disease ▲ from 4.5%

Led 9 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Peking University First Hospital8
  2. Peking University Third Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
6.6%Leads about 1 in 15 of China's research papers on Duchenne muscular dystrophy ▲ from 5.1%

Led 14 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

Hospitals counted here

  1. Peking University First Hospital11
  2. Peking University Third Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
3.7%Leads about 1 in 27 of China's research papers on Behçet disease ▲ from 2.1%

Led 9 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
1
Research papers it led
9
Trials it led
6
Share of China's trials
35.3%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

Hospitals counted here

  1. Peking University People's Hospital5
  2. Peking University International Hospital2
  3. Peking University First Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Comment on: Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China: reply.2023Rheumatology (Oxford, England)
  2. Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'.2023Annals of the rheumatic diseases
  3. Uncharted territory: retinal vasculitis and cryoglobulinemia in Behçet's disease - a case report.2025Frontiers in immunology
  4. Case Report: A Ticking Time Bomb: Femoral Artery Aneurysm as a Complication of Behcet's Disease in Adolescents.2024International journal of rheumatic diseases
  5. Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.2024Clinical and experimental medicine
Trials on ClinicalTrials.gov6
  1. BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNCT06794008Lead sponsorPhase 2Start 2024-12
  2. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  3. AutoInflammatory Disease Alliance Registry (AIDA)RecruitingNCT05200715Study siteStart 2020-08
  4. Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.Not yet recruitingNCT07833163Lead sponsorPhase 2Start 2026-09
  5. Ivarmacitinib for Refractory Behcet's SyndromeWithdrawnNCT07634848Lead sponsorPhase 2Start 2026-06
  6. Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic SyndromeCompletedNCT07582991Lead sponsorPhase 2Start 2024-03

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
17.2%Leads about 1 in 6 of China's research papers on Alport syndrome ▼ from 22.2%

Led 10 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.8%
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 0020242025: 112025

Hospitals counted here

  1. Peking University First Hospital8
  2. Peking University Shenzhen Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
9.4%Leads about 1 in 11 of China's research papers on IgA nephropathy

Led 69 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
1
Research papers it led
69
Trials it led
5
Share of China's trials
4.2%
Share of the world's papers
4.0%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 3320242025: 002025

Hospitals counted here

  1. Peking University First Hospital65
  2. Peking University Third Hospital1
  3. Peking University International Hospital1
  4. Peking University Shenzhen Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.2022JAMARCT
  2. Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.2026Journal of the American Society of Nephrology : JASNRCT
  3. Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.2024Kidney360RCT
  4. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.2024Kidney internationalRCT
  5. Targeted release of budesonide in primary IgA nephropathy.2024Lancet (London, England)
Trials on ClinicalTrials.gov6
  1. To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic StrategiesRecruitingNCT07822100Lead sponsorN/AStart 2026-08
  2. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Study sitePhase 3Start 2026-04
  3. A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA NephropathyRecruitingNCT07582133Study sitePhase 2Start 2026-07
  4. A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.RecruitingNCT07375758Study sitePhase 1/Phase 2Start 2026-02
  5. Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular DiseasesRecruitingNCT07614477Study sitePhase 2Start 2026-05
  6. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
4.0%Leads about 1 in 25 of China's research papers on Osteogenesis imperfecta ▲ from 3.1%

Led 4 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 002025

Hospitals counted here

  1. Peking University People's Hospital2
  2. Peking University Shenzhen Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
2.3%Leads about 1 in 43 of China's research papers on Primary biliary cholangitis

Led 7 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Peking University People's Hospital7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
12.5%Leads about 1 in 8 of China's research papers on Inherited epidermolysis bullosa ▲ from 4.8%

Led 7 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025

Hospitals counted here

  1. Peking University First Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
3.4%Leads about 1 in 29 of China's research papers on Familial adenomatous polyposis

Led 2 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Peking University First Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov